HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00081068 ·Status: WITHDRAWN ·Phase: PHASE2

Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy

NCT00185393 ·Status: COMPLETED ·Phase: PHASE3

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy

NCT00047164 ·Status: COMPLETED ·Phase: PHASE1

Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma

NCT02051257 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma

NCT02624258 ·Status: TERMINATED ·Phase: EARLY_PHASE1

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

NCT01853631 ·Status: RECRUITING ·Phase: PHASE1

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

NCT06090864 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

NCT05138458 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2

Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

NCT00094848 ·Status: COMPLETED ·Phase: PHASE2

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma

NCT04128072 ·Status: RECRUITING ·Phase: PHASE2

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT02953652 ·Status: COMPLETED ·Phase: PHASE2

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

NCT00867529 ·Status: COMPLETED ·Phase: PHASE2

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

NCT04526834 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00004874 ·Status: TERMINATED ·Phase: PHASE3

The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

NCT00441025 ·Status: TERMINATED ·Phase: PHASE2

Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma

NCT00378768 ·Status: COMPLETED ·Phase: PHASE2

Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients

NCT04696705 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

NCT05453396 ·Status: RECRUITING ·Phase: PHASE2

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

NCT00048555 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

NCT03778619 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

NCT04083495 ·Status: RECRUITING ·Phase: PHASE2

Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

NCT00117975 ·Status: COMPLETED ·Phase: PHASE2

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

NCT04082936 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

NCT00354926 ·Status: COMPLETED ·Phase: PHASE1

Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma

NCT01446562 ·Status: COMPLETED ·Phase: PHASE2